Provided by Tiger Fintech (Singapore) Pte. Ltd.

VanEck Environmental Services ETF

37.30
+0.07970.21%
Post-market: 37.300.00000.00%16:05 EDT
Volume:4.48K
Turnover:166.41K
Market Cap:82.43M
PE:64.70
High:37.30
Open:36.95
Low:36.95
Close:37.22
Loading ...

Listen up, car dealers – you need to start selling EVs the way you sell tow rigs

Electrek
·
06 May

Ecolab Navigates Soft Demand, Tariffs With Margin Gains, Confirms Full-Year Forecast

Benzinga
·
30 Apr

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

GlobeNewswire
·
28 Apr

BMW is selling more EVs than Audi and Mercedes COMBINED – here’s why

Electrek
·
24 Mar

BMW iX snatches the top spot in J.D. Power EV satisfaction survey

Electrek
·
03 Mar

Donaldson Q2 Earnings Miss: Aftermarket And Life Sciences Segments Shine Amid Revenue Dip

Benzinga
·
27 Feb

Hyundai IONIQ 6 Named the Highest-Ranking Mass-Market BEV in J.D. Power 2025 U.S. Electric Vehicle Experience Ownership Study

PR Newswire
·
27 Feb

Evaxion Biotech extends Phase 2 trial with EVX-01 to enhance clinical data

TIPRANKS
·
25 Feb

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

GlobeNewswire
·
25 Feb

Ecolab Q4: Solid EPS Growth, Industrial And Institutional Acceleration, 2025 Momentum And More

Benzinga
·
11 Feb

BRIEF-Vaneck Announces Change To ETF Product Line

Reuters
·
25 Jan

Vaneck- Vaneck ETF Trust Approved a 5-for-1 Forward Stock Split for Vaneck Environmental Services ETF

THOMSON REUTERS
·
25 Jan

Evaxion Biotech completes dosing in phase 2 trial with EVX-01

TIPRANKS
·
15 Jan

Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01

GlobeNewswire
·
15 Jan

BRIEF-Evaxion Announces Positive Preclinical Data For Cytomegalovirus Vaccine Program EVX-V1

Reuters
·
12 Nov 2024

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

GlobeNewswire
·
12 Nov 2024